Prothena Corp. (Nasdaq: PRTA) entered a global collaboration agreement with Celgene Corp. (Nasdaq: CELG) to develop new therapies for neurodegenerative diseases. Shares of Prothena leaped $4.87 to close at $38.72 while Celgene stock edged up 4 cents to close at $88.31.
